Prodrugs: design and clinical applications

By J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, Dooman Alexander Oh, T. Järvinen, J. Savolainen. Nature reviews. Drug discovery, 2008

1,475 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Artificial intelligence to deep learning: machine intelligence approach for drug discovery (2021, background): “…with a small number of people; Phase 2, drug efficacy testing with the small number of human subjects affected by a particular disease; Phase 3, efficacy studies with a large number of patients and after passing the clinical trials FDA reviews it for approval and commercialization [451, 452].”
Predicting drug metabolism: experiment and/or computation? (2015, background): “Categories of drugs with respect to their metabolic behaviour Prodrugs are medicinal compounds whose complete, or nearly complete therapeutic potential is based on the activity of the metabolite(s) 107-111 .”
Microbial siderophores and their potential applications: a review (2016, background): “Although natural sideromycin showed better antimicrobial activity, in many cases, the sideromycin-mediated antibiotics suffered from poor solubility, chemical instability, inadequate absorption, and tissue penetration (Rautio et al. 2008).”
From carbohydrate leads to glycomimetic drugs (2009, methodology): “Possible strategies to improve passive absorption are the bioisoteric replacement of crucial groups 150 or a pro drug approach 151 .”